1. Home
  2. BENF vs ATNM Comparison

BENF vs ATNM Comparison

Compare BENF & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beneficient

BENF

Beneficient

HOLD

Current Price

$1.05

Market Cap

34.2M

Sector

Finance

ML Signal

HOLD

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

SELL

Current Price

$1.13

Market Cap

31.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
BENF
ATNM
Founded
2003
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.2M
31.4M
IPO Year
2023
2013

Fundamental Metrics

Financial Performance
Metric
BENF
ATNM
Price
$1.05
$1.13
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $3.60
AVG Volume (30 Days)
★ 9.4M
102.2K
Earning Date
11-13-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 14.17
EPS
N/A
★ 0.71
Revenue
N/A
★ $90,000.00
Revenue This Year
N/A
$19,344.45
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$1.49
Revenue Growth
N/A
★ 11.11
52 Week Low
$0.50
$0.74
52 Week High
$60.00
$1.74

Technical Indicators

Market Signals
Indicator
BENF
ATNM
Relative Strength Index (RSI) 45.39 51.40
Support Level $0.50 $0.96
Resistance Level $3.81 $1.13
Average True Range (ATR) 0.15 0.08
MACD 0.01 -0.01
Stochastic Oscillator 31.00 58.62

Price Performance

Historical Comparison
BENF
ATNM

About BENF Beneficient

Beneficient is a technology-enabled financial services holding company providing liquidity solutions and trust products and services to participants in the alternative assets industry through an online platform, AltAccess. Its services are focused on alternative asset investors, institutional investors, family offices, and fund managers. The company provides liquidity solutions for alternative asset investments through financing and trust structures. The company has three reportable segments consisting of Ben Liquidity, Ben Custody and Customer ExAlt Trusts. The majority of revenue is derived from the Ben Liquidity segment in the form of interest income.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

Share on Social Networks: